Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must be diagnosed with treatment-refractory neuroblastoma with no known curative treatment options. Tumor histology should be verified at diagnosis or relapse.~* Prior to enrollment, a determination of residual disease must be performed~* Patients must have a Lansky or Karnofsky performance scale score of ≥ 50%.~* Patients must have a life expectancy of ≥ 2 months (8 weeks).~* Total absolute neutrophil count (ANC) is at least 750, Hgb≥8 grams/dl, and plts ≥ 75K. PRBC transfusions are allowed.~* Patients with bone marrow disease will not evaluable for hematologic toxicity. These patients must have a peripheral absolute neutrophil count~  * 750, platelet count ≥ 50K and Hgb ≥8 grams/dl. Transfusions are permitted to meet both the platelet and hemoglobin criteria.~* Creatinine clearance or radioisotope GFR \> 70mL/min/1.73 m2 or a serum creatinine based on age/gender as follows:~* ≤ 0.8 mg/dL (for patients 2 to 5 years of age)~* ≤ 1.0 mg/dL (for patients 6 to 9 years of age)~* ≤ 1.2 mg/dL (for patients 10 to 12 years of age)~* ≤ 1.4 mg/dL (for female patients ≥ 13 years of age)~* ≤ 1.5 mg/dL (for male patients 13 to 15 years of age)~* ≤ 1.6 mg/dL (for male patients ≥ 16 years of age)~* Total bilirubin ≤ 2.5 x upper limit of normal (ULN) for age, and~* SGPT (ALT) \< 2.5 x upper limit of normal (ULN) for age.~* SOS (sinusoidal obstruction syndrome, formerly known as veno-occlusive disease \[VOD\]), if present, should be stable or improving.~* Shortening fraction of \> 27% by echocardiogram, or ejection fraction of \> 55% by radionuclide angiography.~* No evidence of dyspnea at rest. If PFTs are performed, FEV1/FVC \> 60% by pulmonary function test.~* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled.~* CNS toxicity \< Grade 2.~Exclusion Criteria:~* Females of childbearing potential must have a negative pregnancy test.~* Patients of childbearing potential must agree to use an effective birth control method.~* Female patients who are lactating must agree to stop breast-feeding.~* All patients and/or their parents or legal guardians must sign a written informed consent.~* All institutional requirements for human studies must be met.~* Previous treatment with anti-GD2 and interleukin2 therapy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid and Interleukin-2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).